Effects of fluconazole, amphotericin B, and caspofungin on Candida albicans biofilms under conditions of flow and on biofilm dispersion

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3591-3593

  Uppuluri, Priya ^a   Srinivasan, Anand ^b   Ramasubramanian, Anand ^a,b   Lopez Ribot, Jose L ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b The University of Texas at San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FLUCONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL VIABILITY; CONTROLLED STUDY; DISPERSION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; ECHINOCANDINS; FLUCONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 79959225684     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01701-10     Document Type: Article

References (23)

1. Al-Fattani, M. A., and L. J. Douglas. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance. J. Med. Microbiol. 55:999-1008.
2. Bachmann, S. P., et al. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596.
3. Blankenship, J. R., and A. P. Mitchell. 2006. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9:588-594.
4. Chandra, J., et al. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183:5385-5394. (Pubitemid 32802612)
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Honraet, K., E. Goetghebeur, and H. J. Nelis. 2005. Comparison of three assays for the quantification of Candida biomass in suspension and CDC reactor grown biofilms. J. Microbiol. Methods 63:287-295.
7. Jabra-Rizk, M. A., W. A. Falkler, and T. F. Meiller. 2004. Fungal biofilms and drug resistance. Emerg. Infect. Dis. 10:14-19.
8. Kuhn, D. M., T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.
9. Mukherjee, P. K., D. V. Chand, J. Chandra, J. M. Anderson, and M. A. Ghannoum. 2009. Shear stress modulates the thickness and architecture of Candida albicans biofilms in a phase-dependent manner. Mycoses 52:440-446.
10. Mukherjee, P. K., and J. Chandra. 2004. Candida biofilm resistance. Drug Resist. Updat. 7:301-309.
11. Nett, J., et al. 2007. Putative role of beta-1,3-glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520.
12. Nett, J. E., M. T. Cain, K. Crawford, and D. R. Andes. 2011. Optimizing a Candida biofilm microtiter plate model for measurement of antifungal susceptibility by XTT assay. J. Clin. Microbiol. 49:1426-1433.
13. Nett, J. E., K. Crawford, K. Marchillo, and D. R. Andes. 2010. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob. Agents Chemother. 54:3505-3508.
14. Nett, J. E., K. M. Guite, A. Ringeisen, K. A. Holoyda, and D. R. Andes. 2008. Reduced biocide susceptibility in Candida albicans biofilms. Antimicrob. Agents Chemother. 52:3411-3413.
15. Perumal, P., S. Mekala, and W. L. Chaffin. 2007. Role for cell density in antifungal drug resistance in Candida albicans biofilms. Antimicrob. Agents Chemother. 51:2454-2463.
16. Pierce, C. G., et al. 2008. A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. Nat. Protoc. 3:1494-1500.
17. Ramage, G., K. Vande Walle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.
18. Ramage, G., K. VandeWalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636.
19. Ramage, G., K. Vandewalle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Characteristics of biofilm formation by Candida albicans. Rev. Iberoam. Micol. 18:163-170.
20. Ramage, G., B. L. Wickes, and J. L. Lopez-Ribot. 2008. A seed and feed model for the formation of Candida albicans biofilms under flow conditions using an improved modified Robbins device. Rev. Iberoam. Micol. 25:37-40.
21. Uppuluri, P., A. K. Chaturvedi, and J. L. Lopez-Ribot. 2009. Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia 168:101-109.
22. Uppuluri, P., et al. 2010. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 6:e1000828.
23. Uppuluri, P., H. Dinakaran, D. P. Thomas, A. K. Chaturvedi, and J. L. Lopez-Ribot. 2009. Characteristics of Candida albicans biofilms grown in a synthetic urine medium. J. Clin. Microbiol. 47:4078-4083.